MedWatch

Analysis: The growth of the Danish drug market

The development on the Danish drug market in the noughties and the current decade respectively could not be more different.

Foto: PEDERSEN RUNE

In spite of a steady flow of new drugs against a number of diseases being launched in recent years, public bodies have managed to enforce a dramatic shift in the rise in drug costs. The basis is a tough stance from the Danish regions towards the drug industry due to budget tightening, and the stance has reduced yearly growth rates significantly.

Allerede abonnent? Log ind.

Læs hele artiklen

Få adgang i 14 dage for 0 kr.
Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.

  • Adgang til alle låste artikler
  • Modtag vores daglige nyhedsbreve
  • Fuld adgang til vores app
Der skete en fejl. Prøv venligst igen senere

Få fuld adgang til dig og dine kollegaer.

Start et gratis virksomhedsprøveabonnement

Mere fra MedWatch

Seneste nyt

MedWatch job

Se flere jobs

Se flere jobs

Watch job

Se flere jobs

Se flere jobs

Latest news

Seneste nyt fra Watch Medier